Effect of Entrectinib/Luo Shengquan Combination Chemotherapy

Entrectinib (Entrectinib) is a targeted drug mainly used to treat patients with NTRK gene fusion-positive, ROS1 gene fusion-positive and EGFR-mutated non-small cell lung cancer . Entrectinib prevents tumor cell proliferation and spread by inhibiting abnormal kinase activities in pathways such as neurogenic receptor kinase (TRK), ROS1 and ALK. In recent years, clinical studies have shown that the combined use of entrectinib and chemotherapy can significantly enhance the therapeutic effect and improve the quality of life of patients.

The treatment regimen of entrectinib combined with chemotherapy has shown better clinical efficacy than single treatment, especially in the treatment of some complex tumor types. Traditional chemotherapy drugs achieve therapeutic effects by inhibiting the division and proliferation of tumor cells, but the single use of chemotherapy is often accompanied by high drug resistance and side effects. The targeting effect of entrectinib can effectively inhibit the mutation of specific cancer genes while reducing damage to normal cells, thereby achieving a precise attack on tumors. The advantage of combination chemotherapy is that chemotherapy drugs broadly inhibit the growth of tumor cells, while entrectinib targets specific gene mutations to provide more targeted treatment. This combination strategy enhances treatment efficacy, especially in patients who develop resistance to single treatments.

For example, entrectinib has shown good efficacy in certain lung cancers, liver cancers, and soft tissue tumors when used in combination with chemotherapy. Entrectinib can significantly delay disease progression and improve patients' overall survival. During the process of combination chemotherapy, patients often experience enhanced efficacy. At the same time, by adjusting the dosage and type of chemotherapy drugs, the occurrence of adverse reactions can be reduced and tolerance can be improved. Therefore, entrectinib combined with chemotherapy is of great significance in the treatment of some refractory cancers.

Reference materials:https://www.roche.com/products/rozlytrek